KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Cash Flow (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Cash Flow for 13 consecutive years, with $94.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 68.46% to $94.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.0 million, a 1414.7% increase, with the full-year FY2025 number at $56.0 million, up 1414.7% from a year prior.
  • Net Cash Flow was $94.8 million for Q4 2025 at Xenon Pharmaceuticals, up from -$30.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $254.3 million in Q2 2022 to a low of -$263.8 million in Q3 2022.
  • A 5-year average of $6.4 million and a median of $5.6 million in 2021 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 5427.59% in 2022; the steepest drop was 5053.06% in 2022.
  • Xenon Pharmaceuticals' Net Cash Flow stood at $87.8 million in 2021, then crashed by 153.59% to -$47.1 million in 2022, then skyrocketed by 203.74% to $48.8 million in 2023, then increased by 15.21% to $56.2 million in 2024, then surged by 68.46% to $94.8 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Net Cash Flow are $94.8 million (Q4 2025), -$30.9 million (Q3 2025), and $18.1 million (Q2 2025).